Grants > Beta-Amyloid Peptide/a2-Macroglobulin Interactions
Updated On: Ene. 19, 2025
Alzheimer's Disease Research Grant
Beta-Amyloid Peptide/a2-Macroglobulin Interactions
About the Research Project
Program
Alzheimer's Disease Research
Award Type
Standard
Award Amount
$199,523
Active Dates
April 01, 1999 - March 31, 2001
Grant ID
A1999011
Summary
It has been suggested that the protein a2-macroglobulin (a2M) could be an inhibitor of beta-amyloid (Ab) aggregation. The goal of this study is to elucidate the nature of the interaction between a2M and the Ab peptide. Dr. Gonias will accomplish this by first identifying the site in a2M which binds to Ab. Because a2M also has important interactions with various growth factors and cytokines that have been implicated in Alzheimer's disease, Dr. Gonias will also attempt to determine if a2M-Ab interaction alters a2M binding to cytokines. One possible outcome of these studies is the identification of novel peptides that have the ability to alter Ab fibril formation -- an activity with potential therapeutic value for Alzheimer's disease.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD